Company Filing History:
1 out of 26 
1 out of 10 Years Active: 2023
Title: **Xianyang Jiang: Innovator in Cell Therapy**
Introduction
Xianyang Jiang is a prominent inventor based in Shanghai, China, known for his innovative contributions to the field of cell therapy. With a patent portfolio that includes groundbreaking advancements in vaccine development and T cell responses, he has established himself as a significant figure in the realm of medical research and therapeutic solutions.
Latest Patents
Xianyang Jiang holds a notable patent titled "Vaccine and uses thereof in cell therapy." This patent focuses on compositions and methods designed to enhance T cell responses in vivo. Specifically, it describes a method for treating subjects with cancer by administering modified cells to enhance the immune system’s response against antigens associated with solid tumors. The innovation incorporates various techniques, including the delivery of nucleic acids encoding therapeutic agents and the use of modified cells targeting specific antigens.
Career Highlights
Throughout his career, Xianyang Jiang has been associated with leading companies in the biotechnology field, most notably Innovative Cellular Therapeutics Holdings, Ltd., and Innovative Cellular Therapeutics, Inc. His work has significantly impacted the development of cell-based therapies, positioning him as a thought leader in enhancing immunotherapy for cancer treatment.
Collaborations
Xianyang Jiang has collaborated with key professionals in the industry, including Lei Zhang and Zhiyuan Cao. Their collective expertise has contributed to advancing research and development in cellular therapeutics, fostering innovation in treatments for cancer and other serious conditions.
Conclusion
Xianyang Jiang's contributions to the field of cell therapy exemplify the potential of innovative approaches in medicine. His patent for enhancing T cell response through modified cells underscores the importance of creativity and collaboration in advancing healthcare solutions. As research continues, his work will undoubtedly inspire future developments in cancer immunotherapy and beyond.